Lisata Therapeutics (LSTA) has key developments to watch, all revolving around its investigational drug, Certepetide.
Certepetide works by targeting specific alpha-v integrins (receptors) that are primarily expressed and overexpressed on tumor endothelial cells and tumor cells while sparing healthy tissue.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com